Agilex Biolabs provides world-class toxicology services via its purpose-built GLP compliant facility in Brisbane, Australia. In collaboration with Attentive Science, we provide our clients with a comprehensive solution to conduct full-service IND-enabling toxicology services to support global nonclinical drug development programs. Eligible biotechs can take advantage of the 43.5% cash rebate to conduct their toxicology studies in Australia, through this generous Research and Development (R&D) Tax Scheme.
About this webinar
Australia is a highly attractive destination for first in-human clinical studies supporting the development of novel therapies and vaccines. Through this streamlined regulatory process, defendable quality data from clinical trials which is globally acceptable to FDA and EMA, along with 43.5% cash rebate on toxicology activities in addition to the clinical trials being run in Australia makes it an ideal designation to accelerate your drug development programs.